AEterna Zentaris signed an exclusive licence agreement with Specialised Therapeutics Asia for Zoptrex, covering the territories of Australia and New Zealand. It is the fourth licensing agreement for AEterna’s lead anti-cancer compound.
AEterna will receive an up-front payment plus milestone payments and royalties, while Ergomed will receive a portion of all revenues generated from the commercialisation of the product.
Zoptrex is currently in a fully-enrolled Phase 3 clinical trial for patients with cancer of the womb or uterus. If the results of the trial warrant doing so, AEterna will submit a new drug application for Zoptrex to the United States Food and Drug Administration in 2017.
“This licensing agreement for Australia and New Zealand adds another two territories to the overall coverage now for Zoptrex and demonstrates the value of our co-development business,” said Dr Miroslav Reljanovic.
“In line with our strategy to expand our co-development business, we also recently announced a new partnership, which, together with this licensing agreement, further validates our hybrid business model,” he added.
Story by ProactiveInvestors